| Bioactivity | Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells[1][2][3][4]. | ||||||||||||
| Invitro | Luxeptinib (MEC-1 CLL cells; 0.1~10 µM; 72 hours) inhibits cells proliferation with an IC50 of 32 nM[1].Luxeptinib inhibits BCR signaling-induced phosphorylation of BTK, PLCg2, AKT, ERK1/2, S6 ribosomal protein and strongly suppresses SYK phosphorylation in primary chronic lymphocytic leukemia (CLL) cells[1]. Luxeptinib (MV4-11 cells; 500 pM; 1 hour) completely inhibits phosphorylation of FLT3 and STAT5[2]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | Luxeptinib | ||||||||||||
| CAS | 1616428-23-9 | ||||||||||||
| Formula | C25H17F4N5O2 | ||||||||||||
| Molar Mass | 495.43 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Luxeptinib
CAS: 1616428-23-9 F: C25H17F4N5O2 W: 495.43
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.